Seagen's Proposed Pfizer Transaction On-Track And Anticipated To Close In Late-2023 or Early-2024, Subject to Closing Conditions, With Ongoing FTC Review and Recent European Commission Approval
Portfolio Pulse from Benzinga Newsdesk
Seagen's proposed transaction with Pfizer is expected to close in late-2023 or early-2024, subject to closing conditions. The transaction is currently under review by the FTC and has recently received approval from the European Commission.
November 01, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seagen's proposed transaction with Pfizer is on track and expected to close in late-2023 or early-2024. The deal is currently under FTC review and has received approval from the European Commission.
The news is directly about Seagen's proposed transaction with Pfizer. The deal is expected to close in late-2023 or early-2024, subject to closing conditions. This is a significant event for Seagen and could have a substantial impact on its stock price. However, the impact is not immediate as the deal is expected to close in the future and is still subject to regulatory review and closing conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100